- Q4 2023 Intellia Therapeutics Inc Earnings Call TranscriptFeb 22, 2024$27.81 (+4.98%)Earnings
- Intellia Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Q3 2023 Intellia Therapeutics Inc Earnings Call TranscriptNov 09, 2023$25.16 (-11.24%)Earnings
- Q2 2023 Intellia Therapeutics Inc Earnings Call TranscriptAug 03, 2023$39.2 (-1.45%)Earnings
- Intellia Therapeutics Inc To Discuss Interim Clinical Data from Ongoing First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema TranscriptJun 12, 2023
- Intellia Therapeutics Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- Intellia Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q1 2023 Intellia Therapeutics Inc Earnings Call TranscriptMay 04, 2023$43.59 (+11.90%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Intellia Therapeutics Inc Earnings Call TranscriptFeb 23, 2023$38.44 (-1.57%)Earnings
- Intellia Therapeutics Inc Investor Event TranscriptNov 14, 2022
- Q3 2022 Intellia Therapeutics Inc Earnings Call TranscriptNov 03, 2022$52.78 (-3.69%)Earnings
- Intellia Therapeutics Inc at Chardan Genetic Medicines Conference TranscriptOct 03, 2022
- Intellia Therapeutics Inc 2022 Bradykinin Symposium TranscriptSep 16, 2022
- Q2 2022 Intellia Therapeutics Inc Earnings Call TranscriptAug 04, 2022$63.6 (-10.32%)Earnings
- Intellia Therapeutics Inc to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study TranscriptJun 24, 2022
- Q1 2022 Intellia Therapeutics Inc Earnings Call TranscriptMay 05, 2022$51.35Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 15, 2022
- Intellia Therapeutics Inc Call To Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study TranscriptFeb 28, 2022
- Q4 2021 Intellia Therapeutics Inc Earnings Call TranscriptFeb 24, 2022$83.69 (-3.13%)Earnings
- Intellia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Intellia Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) TranscriptNov 15, 2021
- Q3 2021 Intellia Therapeutics Inc Earnings Call TranscriptNov 04, 2021$137.66 (+2.43%)Earnings
- Intellia Therapeutics Inc Strategic Collaboration to Develop Novel Genomic Medicines TranscriptOct 13, 2021
- Q2 2021 Intellia Therapeutics Inc Earnings Call TranscriptAug 05, 2021$166.29 (+24.32%)Earnings
- Intellia Therapeutics Inc Call to Discuss Interim Clinical Data from NTLA-2001 Phase 1 Study Corporate Call TranscriptJun 28, 2021
- Intellia Therapeutics Inc Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences Corporate Call TranscriptJun 22, 2021
- Q1 2021 Intellia Therapeutics Inc Earnings Call TranscriptMay 06, 2021$66.59 (-9.38%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Q4 2020 Intellia Therapeutics Inc Earnings Call TranscriptFeb 25, 2021$60.93 (-0.78%)Earnings
- Intellia Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2020
- Q3 2020 Intellia Therapeutics Inc Earnings Call TranscriptNov 05, 2020$24.4Earnings
- Q2 2020 Intellia Therapeutics Inc Earnings Call TranscriptAug 06, 2020$18.7Earnings
- Intellia Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q1 2020 Intellia Therapeutics Inc Earnings Call TranscriptMay 07, 2020$12.45Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 10, 2020
- Q4 2019 Intellia Therapeutics Inc Earnings Call TranscriptFeb 27, 2020$12.54Earnings
- Q3 2019 Intellia Therapeutics Inc Earnings Call TranscriptOct 31, 2019$10.88Earnings
- Q2 2019 Intellia Therapeutics Inc Earnings Call TranscriptAug 01, 2019$16.78Earnings
- Intellia Therapeutics Inc Annual Shareholders Meeting TranscriptMay 21, 2019
- Q1 2019 Intellia Therapeutics Inc Earnings Call TranscriptMay 02, 2019$14.31 (-15.82%)Earnings
- Intellia Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 12, 2019
Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
Hello, and welcome to Day 1 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, we have Intellia Therapeutics with us and representing Intellia is Ian Karp, SVP of IR and Corporate Communications. Ian, would you like to start off with some opening remarks, then we'll jump into Q&A.
Sure. And thanks so much for having us. Yes, Intellia for those that are a bit new to Intellia, we're one of the leading full spectrum genome managing companies, which really means 3 things. So we're focused in 3 core areas, which is building out a deep gene editing capability and a toolbox that we can use for therapeutic purposes, and we then deploy those tools both on the in vivo and ex vivo side of human therapeutics. So on the in vivo side, we're actually delivering the CRISPR machinery to make those edits typically for -- to address disease-causing proteins or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)